Home Meetings Directions About Us Sponsors Mailing List Links

SCDMDG presents:

Click here to print the meeting flyer and registration form.

Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance
Dr. Richard Kim
Division Chair
Division of Clinical Pharmacology
University of Western Ontario

Drug transporters are now widely appreciated as important determinants governing drug absorption, excretion, and in many cases, extent of drug entry into target organs. There is also a greater appreciation that altered drug transporter function, whether due to genetic polymorphisms, drug-drug interactions, or environmental factors such as dietary constituents, can in many cases result in unexpected drug-induced toxicity in vivo. Not surprisingly, various regulatory agencies including the FDA have become much more aware of the need to better understand the relevance of certain drug transporters as a risk factor for unexpected drug toxicity or drug interactions.

In this presentation, key drug transporters of relevance to ADME will be outlined, with particular focus on the Organic Anion Transporting Polypeptide (OATP) family of drug uptake transporters, efflux transporters such as MDR1, as well as recently identified transporters including OST alpha/beta and MATE1. Importantly, a number of in vitro cell-based systems used for assessing such transporters as well as recent advances in transporter knockout mouse models will be outlined. In addition, the clinical relevance of drug transporters will also be discussed.

Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.

In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.

Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Date: Tuesday April 19. 2011 – 5:00 p.m. (Buffet), 7:00 p.m. (Presentation)
Location: Salk Institute for Biological Studies
10010 North Torrey Pines Road
La Jolla, CA 92037
Price: $20 Registration in advance or at the door (includes buffet dinner and soft drinks)

Space is Limited — Register Early to Guarantee Your Attendance!


Prior presentations:

Note: slides are displayed in a new window, left-click to advance, right-click to go back.

Speaker PDF Topic Date
Dr. Jerry Galluppi Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist October 5, 2010
Dr. Dennis Smith Does drug metabolism hold its future in its own hands? April 27, 2010
Dr. Paul F. Hollenberg Mechanism-Based Inactivation of Human Cytochromes P450 October 6, 2009
Dr. Jack H. Dean
Dr. Thomas Baillie
  Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective May 19, 2009
Eric Johnson, Ph.D.   Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography September 30, 2008
Dr. Kenneth E. Thummel, Ph.D.   Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics May 7, 2008
Dr. Anthony Lu, Ph.D.   Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme? September 12, 2007
Dr. Scott Obach, Ph.D.   Leveraging ADME Data In Metabolites In Safety Testing (MIST) April 18, 2007
Dr. Sidney Nelson, Ph.D.   Drug Metabolism and Chemical Structural Alerts September 27, 2006
Richard B. Kim, MD   Relevance and Utility of Transporters to Drug Discovery and Development September 21, 2005
Dr. Frederick P. Guengerich, Ph.D.   Human Cytochrome P450 2A6 as a Case History:  Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450 April 27, 2005
Dr. Leslie Benet, Ph.D.   Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS September 29, 2004
Dr. Christopher A. Lipinski, Ph.D.   ADME/Tox: How Low Can You Go And How Do You Recover? April 21, 2004


Spring 2011 Meeting Sponsors:

Celsis Tandem Labs Xenotech
Life Technologies Gigatech  

For more information on sponsoring SCDMDG, please refer to our sponsorship guidelines.